Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
A phase 2 trial of RAD101 (18F-FPIA) in brain and spinal cord tumours, run by Radiopharm Theranostics, Ltd, active and no longer recruiting.
Overview
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases is a phase 2 interventional study registered as NCT06777433 by Radiopharm Theranostics, Ltd, with 30 participants enrolled, started 2024-12-13 and due to reach its primary completion in 2026-04-23. Interventions recorded: RAD101 (18F-FPIA).
Similar pages
not linked directly; found by shared links- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Radiopharm Theranostics and the tag pipeline.
- TrialA Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
Shares Radiopharm Theranostics and the tag pipeline.
- TrialTest-retest Evaluation of [18F]F-AraG PET
Shares Fluorine-18 and the tag pipeline.
- TrialImaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Shares Fluorine-18 and the tag pipeline.
- TrialUsing 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Shares Fluorine-18 and the tag pipeline.
- Trial[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Fluorine-18 and the tag pipeline.
- TrialA Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Shares Fluorine-18 and the tag pipeline.
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Fluorine-18 and the tag pipeline.